7 news items
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DRRX
21 May 24
(bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER®
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
DRRX
13 May 24
, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DRRX
7 May 24
, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
DRRX
30 Apr 24
, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DRRX
27 Mar 24
(bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER®
9ns5j5sq6o61ocmpshq7jys2p8bz35ioq97e4
DRRX
20 Mar 24
(bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER®
o78lqi
DRRX
4 Mar 24
utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution
- Prev
- 1
- Next